Evidence map›Paper›PMID 33576954›Full record

ArticleJournal of endocrinological investigation2021

Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy.

C Luongo, R Morra, C Gambale, T Porcelli, F Sessa, E Matano, V Damiano, M Klain, M Schlumberger, D Salvatore

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of endocrinological investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 4 pooled it
3.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 4 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Observational
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

C Luongo *Department of Public Health, University of Naples "Federico II", Via S Pansini, 5, 80131, Naples, Italy. cristinaluongo@gmail.com.ORCID http://orcid.org/0000-0002-9127-4538
R Morra *Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
C Gambale *Department of Public Health, University of Naples "Federico II", Via S Pansini, 5, 80131, Naples, Italy.
T PorcelliDepartment of Public Health, University of Naples "Federico II", Via S Pansini, 5, 80131, Naples, Italy.
F SessaDepartment of Public Health, University of Naples "Federico II", Via S Pansini, 5, 80131, Naples, Italy.
E MatanoDepartment of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
V DamianoDepartment of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
M KlainDepartment of Advanced Biomedical Sciences, University of Naples "Federico II", Naples, Italy.
M SchlumbergerDepartment of Endocrine Oncology, Gustave Roussy, University Paris-Saclay, 94805, Villejuif, France.
D SalvatoreDepartment of Public Health, University of Naples "Federico II", Via S Pansini, 5, 80131, Naples, Italy. domsalva@unina.it.
Federico II University Hospital · ITUniversity of Naples Federico II · ITInstitut Gustave Roussy · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeImmune checkpoint inhibitors (ICIs) are monoclonal antibodies that enhance the immune response against cancer cells. ICIs are generally well tolerated, although endocrine immune-related adverse events (irAEs) are common. We investigated the risk factors for thyroid irAEs in patients treated with ICIs. Moreover, we evaluated the clinical outcome of subjects who became hypothyroid compared to euthyroid patients. PATIENTS AND

methodsWe retrospectively analyzed a series of 195 consecutively subjects treated with ICIs for metastatic tumors at the University of Naples "Federico II" between January 2014 and March 2020. Only subjects tested for thyroid function before and during the treatment with ICIs were included.

resultsIn the 96 patients treated with ICIs who were included [66 males, median age: 62 years (27-87)], thyroid irAEs occurred in 36 (37.5%), 16 (16.7%) a transient thyrotoxicosis, and 20 (20.8%) an hypothyroidism (in nine subjects hypothyroidism was preceded by a transient thyrotoxicosis). Only baseline TSH levels above 1.67 mIU/L and positive anti-thyroid antibodies (Ab-T) were associated with a higher risk of hypothyroidism. Patients with hypothyroidism during ICI treatment showed an improved 2-year PFS (HR = 0.82 CI 0.47-1.43; p = 0.0132) and OS (HR = 0.38 CI 95% 0.17-0.80; p = 0.011) compared to euthyroid patients.

conclusionsBaseline TSH levels above 1.67 mIU/L and presence of Ab-T are risk factors for the development of thyroid irAEs. Patients affected by thyroid irAEs showed a longer survival than patients who remained euthyroid.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalFemaleHumansHypothyroidismImmune Checkpoint InhibitorsImmunotherapyKaplan-Meier EstimateMaleMiddle AgedNeoplasmsProgression-Free SurvivalRetrospective StudiesRisk FactorsAntineoplastic Agents, ImmunologicalImmune Checkpoint InhibitorsThyrotropinAnti-thyroid antibodiesHypothyroidismImmunotherapyThyroid immuno-related adverse events

Identifiers

PMID33576954
PMCPMC8357750
OpenAlexW3126711953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.